FierceBiotech Names Intarcia Therapeutics as
One of the “Fierce 15" Biotech Companies of 2007
Intarcia Therapeutics Announces Final Results From A Phase 2 Study Of Injectable Omega Interferon plus Ribavirin for the Treatment of Hepatitis C Genotype-1
March 19, 2007
Intarcia Raises $50 Million in a Series BB Financing
Nov 15, 2005